Institut des MICI, Clinique Ambroise Paré

Neuilly-sur-Seine 92200

0 studies enrolling now · 3 studies all time

What they study most

Crohns Disease, Moderately to Severely Active Crohns Disease, Moderately to Severely Active Ulcerative Colitis

Studies at this site

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Recruiting now
• Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Running, not enrolling